Minap

Minapharm is an Egypt-based listed pharmaceutical and biopharmaceutical company focused on developing, manufacturing, and commercializing small molecules, biologics, biosimilars, vaccines, and cell and gene therapy products. The company positions itself as the leading biopharmaceutical player in Egypt, Africa, and the Middle East, with integrated capabilities spanning R&D, process development, manufacturing, and regional commercialization. Through subsidiaries including ProBioGen AG, MiGenTra Egypt, and MiGenTra GmbH, it also provides CDMO and proprietary technology services to the global biotech industry. Minapharm markets a broad portfolio of more than 150 medicines and has an internal pipeline of recombinant proteins and biosimilars, including an adalimumab biosimilar that entered Phase 1 clinical testing in Germany. Its business model combines affordable medicines for emerging markets with higher-value biologics, manufacturing, and technology partnerships.